- Bausch Health Canada has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), securing a Letter of Intent (LOI) for PrOKEDI (risperidone extended-release injectable suspension) 75 mg and 100 mg for adults with schizophrenia.
- The LOI marks a key step toward public reimbursement and broader patient access across Canada, with Bausch Health now working with provincial and territorial drug plans to finalize listing agreements.
- PrOKEDI is a once-monthly long-acting injectable antipsychotic designed to achieve therapeutic risperidone levels rapidly and maintain them over four weeks without oral supplementation or a loading dose.
- Healthcare and patient advocates welcomed the development, highlighting the need for additional treatment options to help people living with schizophrenia achieve greater stability, independence, and quality of life.
Takeaways:
The pCPA Letter of Intent for PrOKEDI (risperidone LAI) moves Bausch Health toward public reimbursement and broader access for Canada’s schizophrenia population, with provincial/territorial listing talks now in progress. As a once-monthly long-acting injectable that achieves therapeutic levels rapidly and maintains them for four weeks without loading doses or oral supplementation, PrOKEDI should improve adherence and reduce relapse risk relative to oral antipsychotics.
Source: CA Newswire
